Proton-Pump Inhibitors Are Associated with Chronic Kidney Disease

A further reason to use PPIs only when their clinical benefits are clear

Polypharmacy is one possible cause of the increasing prevalence of chronic kidney disease (CKD) in the U.S. population. Proton-pump inhibitor (PPI) use is associated with acute renal injury, but PPIs also have other biological effects, including hypomagnesemia, that can lead to excess risk for CKD. In a population-based, prospective cohort study, researchers followed 10,482 adults (mean age, 63; 80% white) with normal renal function (estimated glomerular filtration rate, >60 mL/minute/1.73 m²); at baseline, 322 participants used PPIs and 956 participants used histamine-2 (H₂)–receptor antagonists. During the study (median follow-up, 14 years), PPI use increased markedly, to ≈27% of participants.

At study end, the unadjusted incidence of CKD …

Reviewing Author

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Proton-Pump Inhibitors Are Associated with Chronic Kidney Disease

Topics

Reviewing Author